Thomas C Beadnell

Dr. Thomas C Beadnell


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
TBThomas C Beadnell
Thomas C Beadnell
CFC. Fain
C. Fain
CVC.J. Vivian
C.J. Vivian
JKJ.C.G. King
J.C.G. King
RHR. Hastings
R. Hastings
DWD.R. Welch
D.R. Welch

Verified
Journal Article
Open access
PDF file
TBThomas C Beadnell
Thomas C Beadnell
SJSusmita Jasti
Susmita Jasti
RWRuqi Wang
Ruqi Wang
BDBruce Hewat Davis
Bruce Hewat Davis
VLVirginia Litwin
Virginia Litwin
Monitoring chimeric antigen redirected (CAR) T-cells post-infusion in clinical trials is a specialized application of flow cytometry. Unlike the CAR T-cell monitoring for individual patients conducted in clinical laboratories, the data generated during a clinical trial will be used not only to monitor the therapeutic response of a single patient, but determine the success of the therapy itself, or even of an entire class of therapeutic compounds. The data, typically acquired at multiple testing laboratories, will be compiled into a single database. The data may also be used for mathematical modeling of cellular kinetics or to identify predictive biomarkers. With the expanded context of use, a robust, standardized assay is mandatory in order to generate a valuable and reliable data set. Hence, the requirements for assay validation, traceable calibration, technology transfer, cross-instrument standardization and regulatory compliance are high.

26 February 2026 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Closed access
PDF file
AAAhmad Al‐Attar
Ahmad Al‐Attar
TBThomas C Beadnell
Thomas C Beadnell
RDRobert J. Durso
Robert J. Durso
VNVeronica Nash
Veronica Nash
FOFernando Ortiz
Fernando Ortiz
XWXuehai Wang
Xuehai Wang

3 April 2023
Verified
Other
Open access
TBThomas C Beadnell
Thomas C Beadnell
KMKatie M. Mishall
Katie M. Mishall
QZQiong Zhou
Qiong Zhou
SRStephen M. Riffert
Stephen M. Riffert
KWKelsey E. Wuensch
Kelsey E. Wuensch
RSRebecca E Schweppe
Rebecca E Schweppe

3 April 2023
Verified
Other
Open access
TBThomas C Beadnell
Thomas C Beadnell
KMKatie M. Mishall
Katie M. Mishall
QZQiong Zhou
Qiong Zhou
SRStephen M. Riffert
Stephen M. Riffert
KWKelsey E. Wuensch
Kelsey E. Wuensch
RSRebecca E Schweppe
Rebecca E Schweppe
BCPAP, SW1736, C643, Cal62 control (C), dasatinib-resistant (DR), and dasatinib-resistant cells maintained in 2μM dasatinib in response to indicated concentrations of selumetinib (μM) for 72 hours. Growth was measured by Sulforhodamine B.

3 April 2023
Verified
Other
Open access
TBThomas C Beadnell
Thomas C Beadnell
KMKatie M. Mishall
Katie M. Mishall
QZQiong Zhou
Qiong Zhou
SRStephen M. Riffert
Stephen M. Riffert
KWKelsey E. Wuensch
Kelsey E. Wuensch
RSRebecca E Schweppe
Rebecca E Schweppe
A.) IC50 values were calculated using the PRISM software and non-variable slope analysis. Fold increase in sensitivity was calculated based on changes IC50 values in the DasRes + 2μM dasatinib in relation to the DasRes cell line IC50 values.